Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (101-110 of 180) with videos related to

Pageof 18
Sort By:
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|September 23, 2015
Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT)Andrew J Madden, Sumit Rawal, Katie Sandison, et al.
Cancer Chemotherapy and Pharmacology|March 11, 1999
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell linesW C Zamboni, P J Houghton, J L Hulstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenograftsMark D Walsh, Suzan K Hanna, Jeremy Sen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2016
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinomaJames D Byrne, Mohammad R N Jajja, Allison N Schorzman, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2018
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patientsBrittney R Starling, Parag Kumar, Andrew T Lucas, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 25, 2011
Allometric scaling of pegylated liposomal anticancer drugsWhitney P Caron, Harvey Clewell, Robert Dedrick, et al.
Investigational New Drugs|January 1, 1996
Topoisomerase I interactive drugs in children with cancerC F Stewart, W C Zamboni, W R Crom, et al.
Nanomedicine (London, England)|September 28, 2017
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancerAndrew J Madden, Bruce Oberhardt, Dustin Lockney, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastomaW C Zamboni, A J Gajjar, T D Mandrell, et al.
Pageof 18

Showing results (101-110 of 180) with videos related to

Sort By:
Pageof 18
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|September 23, 2015
Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT)Andrew J Madden, Sumit Rawal, Katie Sandison, et al.
Cancer Chemotherapy and Pharmacology|March 11, 1999
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell linesW C Zamboni, P J Houghton, J L Hulstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenograftsMark D Walsh, Suzan K Hanna, Jeremy Sen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2016
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinomaJames D Byrne, Mohammad R N Jajja, Allison N Schorzman, et al.
Cancer Chemotherapy and Pharmacology|October 18, 2018
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patientsBrittney R Starling, Parag Kumar, Andrew T Lucas, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 25, 2011
Allometric scaling of pegylated liposomal anticancer drugsWhitney P Caron, Harvey Clewell, Robert Dedrick, et al.
Investigational New Drugs|January 1, 1996
Topoisomerase I interactive drugs in children with cancerC F Stewart, W C Zamboni, W R Crom, et al.
Nanomedicine (London, England)|September 28, 2017
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancerAndrew J Madden, Bruce Oberhardt, Dustin Lockney, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastomaW C Zamboni, A J Gajjar, T D Mandrell, et al.
Pageof 18